- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…BioSpace · 3d ago↗ source
- Expect a clash at today’s FDA peptide panelThe service members who refused the Covid vaccine, the fastest-growing Ebola outbreak in history, and other health news from Morning RoundsSTAT · 3d ago↗ source
- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing…